Related Experiment Videos
Multifocal motor neuropathy: current concepts and controversies
Eduardo Nobile-Orazio1, Alberto Cappellari, Alberto Priori
1Dino Ferrari Centre and Centre of Excellence for Neurodegenerative Diseases, Department of Neurological Sciences, Milan University, IRCCS Ospedale Maggiore Policlinico, and Humanitas Clinical Institute, Milan, Italy. eduardo.nobile@unimi.it
Muscle & Nerve
|March 17, 2005
Summary
Multifocal motor neuropathy (MMN) is a nerve condition diagnosed by conduction blocks and often linked to anti-GM1 antibodies. This review clarifies diagnosis, pathogenesis, and treatment, including intravenous immunoglobulin (IVIg) therapy.
Area of Science:
- Neurology
- Immunology
Background:
- Multifocal motor neuropathy (MMN) is a distinct peripheral neuropathy.
- It is characterized by multifocal partial motor conduction blocks (CB).
- MMN is frequently associated with anti-GM1 IgM antibodies and responds well to intravenous immunoglobulin (IVIg).
Purpose of the Study:
- To review and clarify unresolved issues in the diagnosis, pathogenesis, and therapy of MMN.
- To discuss the nosological position of MMN relative to other neuropathies.
- To examine the role of conduction blocks, antibodies, and IVIg in MMN.
Main Methods:
- Review of clinical, electrophysiological, and immunological features of MMN.
- Analysis of therapeutic responses, particularly to IVIg.
- Discussion of current research on MMN pathogenesis and treatment.
Main Results:
- MMN diagnosis relies on multifocal motor conduction blocks.
- Anti-GM1 IgM antibodies are common but not universally present.
- High-dose IVIg is the primary treatment, though mechanisms and optimal regimens require further study.
Conclusions:
- Further research is needed to fully understand MMN's pathophysiology and optimize treatment.
- Clarifying diagnostic criteria and therapeutic strategies for MMN is essential.
- Addressing MMN in relation to other immune-mediated neuropathies is crucial.